Lindy Biosciences is a drug-delivery company that develops formulation technologies to enable high-dose biologic medicines to be administered through simple subcutaneous injections rather than intravenous infusions.
What is the vision behind Lindy Biosciences?
We’re trying to change the rhythm of patient care by giving patients easier access to the medications they need. More and more drugs these days are biologics, which have to be injected into the body somehow. If it’s a very high dose, the standard is an IV infusion, which means patients go into a clinic and, in many cases, rely on caregivers to get them there. For chronic conditions where patients need medication weekly or every other week, that has a huge impact on quality of life.
What our technology does is take a high dose of a biologic and condense it down into a volume small enough to be given as a subcutaneous injection. That means a simple syringe or pen device that patients can self-administer at home. It’s quick, about 30 seconds, and then they’re back to their day without travelling, getting hooked up to an IV, or relying on healthcare professionals to administer the medication. They still go to their doctor for standard visits and checks, but they get a lot of time and control back in their lives.
Could you tell us more about your core technology, called Microglassification?
Yes, it’s a dehydration technology. We use solvents to extract all of the water from protein droplets. The biologic is dissolved in a droplet, we pull the water out, and that pushes the molecules into a very dense microparticle. That microparticle can then be injected in an oily vehicle, so it stays dry and very dense, and after it’s injected, it redissolves in the body.
This helps us deliver a stable product and addresses the main problem with high-dose or high-concentration biologics, which is viscosity. They get really thick, like trying to inject honey through a needle. With our approach, the particles free-flow through a fine gauge needle, and then once they’re in the body they can re-dissolve.
Is this approach agnostic in terms of the therapy it’s applied to?
Yes, that’s one of the benefits. We’re definitely therapeutic agnostic and treatment-area agnostic. It works across the board with biologics.
That flexibility is a core part of why the platform is compelling. The goal is to enable patients to receive high-dose biologics in a format that’s practical for at-home administration, regardless of the specific therapeutic area.
Can you give examples of treatment areas where this could significantly improve quality of life?
Common applications would be autoimmune, oncology, and neurologic treatments. In autoimmune, for example, patients often need constant treatment. They may need to take it for the rest of their lives, or at least through a period of time if they’re experiencing a flare-up.
The most common molecules we work with are monoclonal antibodies because they frequently require very high doses. We’ve also applied the technology to peptides, which are very small biologics. We can do bispecific antibodies, antibody fragments, really anything protein-based works very well with it, and we also have some experience with oligonucleotides.
Collaborations seem to be essential for your model…
Yes, we work via partnerships. The one collaboration that is public is with Novartis. It was a licensing deal we signed in 2024 that gave them exclusive rights to multiple targets, with exclusivity around the molecular target in the body.
Unfortunately, I’m not allowed to talk about which products we’re working on. But that collaboration is a good example of how we structure deals and how our technology can be integrated into a partner’s development programmes.
You’ve also partnered with a CDMO, Lifecore Biomedical. What is its purpose?
As a company, we stay focused on the formulation development piece of a product. We collaborate with pharma that brings us the molecule, and then we collaborate with a CDMO to run our process and produce clinical materials.
Lifecore is the CDMO we’ve selected, and we’ve got a GMP line at their facility in Minnesota. That partnership supports our ability to translate our process into clinical manufacturing while keeping our internal focus on the formulation side.
What are you currently working on in terms of innovation?
In terms of innovation, we’re focused mostly on expanding the applications of the technology. That includes further optimising formulations and increasing the dose we can deliver. We’re also looking at other applications in drug delivery.
That could include extended release and other modes of delivery beyond subcutaneous injection. There are other applications for the technology, and there are also new technologies we can look at.
Are you in high demand currently?
We do have other companies reaching out. We’re a relatively small company, and we need to expand as we get new collaborations. There’s no shortage of demand.
This is a broad challenge in the industry. There are a lot more drugs available than patients actually have access to and take. Between a doctor writing a prescription, a patient getting it filled, using it, and refilling it, there’s a big drop-off at each step. Part of that is access, and if taking your medication is very complicated and has a major quality-of-life impact, fewer patients are going to do it. Pharma recognises this, and there’s a big push to enable patients to take medication at home quickly and in their own control.
What are you going to expand your delivery capabilities?
We are expanding and looking to meet that demand. At the same time, there’s a balance. We want to grow and meet demand, but scaling takes real focus and capacity, and we’re building toward that.
Are you struggling to get the right investment for that expansion, or is it more about growing organically and not too fast?
I would say it’s both. A big part of it is investment, and investment is always a challenge. Fundraising takes a lot of time, and it also takes time away from running the company, because you have to speak with investors and go through that process.
So there’s always a balance there. We’re working to expand, but doing that while managing fundraising and execution is part of the reality for a company at our stage.
Where do you see the company one or two years from now?
One or two years from now, we will have our first clinical data with collaborators. We would also have multiple collaborators that we could likely talk about, as opposed to only having one public one now. And I hope we’ll be expanding the technology as well.
